CN1726016A - 阿尔茨海默氏病的预防和治疗 - Google Patents

阿尔茨海默氏病的预防和治疗 Download PDF

Info

Publication number
CN1726016A
CN1726016A CNA2003801059727A CN200380105972A CN1726016A CN 1726016 A CN1726016 A CN 1726016A CN A2003801059727 A CNA2003801059727 A CN A2003801059727A CN 200380105972 A CN200380105972 A CN 200380105972A CN 1726016 A CN1726016 A CN 1726016A
Authority
CN
China
Prior art keywords
alkyl
bile acid
inhibitors
reuptake inhibitor
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801059727A
Other languages
English (en)
Chinese (zh)
Inventor
T·康东
L·普拉迭尔
J·贝纳维德
H·霍耶尔
H-L·舍费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CN1726016A publication Critical patent/CN1726016A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CNA2003801059727A 2002-12-12 2003-12-10 阿尔茨海默氏病的预防和治疗 Pending CN1726016A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
FR0215722 2002-12-12

Publications (1)

Publication Number Publication Date
CN1726016A true CN1726016A (zh) 2006-01-25

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801059727A Pending CN1726016A (zh) 2002-12-12 2003-12-10 阿尔茨海默氏病的预防和治疗

Country Status (22)

Country Link
EP (1) EP1572174A1 (enExample)
JP (1) JP2006514063A (enExample)
KR (1) KR20050084250A (enExample)
CN (1) CN1726016A (enExample)
AR (1) AR042354A1 (enExample)
AU (1) AU2003296802A1 (enExample)
BR (1) BR0317280A (enExample)
CA (1) CA2507945A1 (enExample)
CO (1) CO5700712A2 (enExample)
FR (1) FR2848452B1 (enExample)
HR (1) HRP20050534A2 (enExample)
MA (1) MA27500A1 (enExample)
MX (1) MXPA05005556A (enExample)
NO (1) NO20053341L (enExample)
NZ (1) NZ540496A (enExample)
PE (1) PE20040770A1 (enExample)
PL (1) PL377110A1 (enExample)
RS (1) RS20050420A (enExample)
RU (1) RU2005121909A (enExample)
TW (1) TW200503707A (enExample)
WO (1) WO2004062652A1 (enExample)
ZA (1) ZA200504656B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107375932A (zh) * 2011-10-28 2017-11-24 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CN107375291A (zh) * 2011-10-28 2017-11-24 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP2007509898A (ja) 2003-11-03 2007-04-19 プロビオドルグ エージー 神経障害治療に有用な組合せ
US7304086B2 (en) 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
TWI489983B (zh) * 2007-05-22 2015-07-01 Otsuka Pharma Co Ltd 用於治療阿茲海默症之藥劑

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
ATE231723T1 (de) * 1991-02-22 2003-02-15 Howard K Shapiro Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe
AU3585397A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
ATE320803T1 (de) * 1998-01-28 2006-04-15 Warner Lambert Co Verfahren zur behandlung von alzheimerschen krankheit
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
US20010028895A1 (en) * 2000-02-04 2001-10-11 Bisgaier Charles L. Methods of treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107375932A (zh) * 2011-10-28 2017-11-24 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CN107375291A (zh) * 2011-10-28 2017-11-24 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
US11229661B2 (en) 2011-10-28 2022-01-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US11376251B2 (en) 2011-10-28 2022-07-05 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US12145959B2 (en) 2011-10-28 2024-11-19 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
US12350267B2 (en) 2011-10-28 2025-07-08 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

Also Published As

Publication number Publication date
RU2005121909A (ru) 2006-01-20
HRP20050534A2 (en) 2006-11-30
NZ540496A (en) 2008-04-30
RS20050420A (sr) 2007-04-10
WO2004062652A1 (fr) 2004-07-29
AU2003296802A1 (en) 2004-08-10
JP2006514063A (ja) 2006-04-27
CA2507945A1 (fr) 2004-07-29
CO5700712A2 (es) 2006-11-30
MXPA05005556A (es) 2005-07-26
EP1572174A1 (fr) 2005-09-14
ZA200504656B (en) 2006-08-30
TW200503707A (en) 2005-02-01
PE20040770A1 (es) 2004-12-10
BR0317280A (pt) 2005-11-08
FR2848452B1 (fr) 2007-04-06
NO20053341D0 (no) 2005-07-08
NO20053341L (no) 2005-09-07
AR042354A1 (es) 2005-06-15
MA27500A1 (fr) 2005-08-01
KR20050084250A (ko) 2005-08-26
PL377110A1 (pl) 2006-01-23
FR2848452A1 (fr) 2004-06-18

Similar Documents

Publication Publication Date Title
EP3721882B1 (en) Treatment of pituitary pars intermedia dysfunction in equine animals
CN1845729A (zh) 包括i.a.维生素c,镁,绿茶提取物的延缓心血管疾病的药物组合物
JP7202892B2 (ja) 非アルコール性脂肪性肝疾患の予防及び治療薬
JP5302900B2 (ja) 脂肪性肝疾患の治療用医薬組成物
US11938122B2 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
CN1726016A (zh) 阿尔茨海默氏病的预防和治疗
CN1145482C (zh) 泛喹酮在治疗阿尔茨海默氏病中的用途
CN101039667A (zh) 双相性精神障碍和相关症状的治疗
EP2615094A2 (en) Sesterterpene compounds and use thereof
US20040138145A1 (en) Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
EP3909568B1 (en) Prophylactic or therapeutic drug for neurodegenerative diseases
HK1083453A (en) Prevention and treatment of alzheimer's disease
CN1365287A (zh) 含有西布曲明和脂酶抑制剂的药物组合物
KR102896709B1 (ko) 신경 변성 질환의 예방 또는 치료약
EP4483874A1 (en) Novel compound, and composition for preventing, alleviating or treating bacterial inflammation and inflammasome-mediated diseases, comprising same as active ingredient
JP2024042690A (ja) 非アルコール性脂肪性肝疾患の予防及び／又は治療薬
HK40014768A (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
HK40014768B (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
JP2025525896A (ja) 新規なヘテロシクリル－フェニル－メチルアミン誘導体、その製造方法及びその多発性硬化症予防、改善、又は治療用途
HK1029937B (en) Use of phanquinone for the treatment of alzheimer's disease
HK40012325A (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083453

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060125

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1083453

Country of ref document: HK